Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Phil Skolnick

Showing results (21-30 of 59) with videos related to

Pageof 6
Sort By:
Clinical Pharmacology in Drug Development|July 27, 2023
Pharmacokinetic Properties of an FDA-approved Intranasal Nalmefene Formulation for the Treatment of Opioid OverdoseRoger Crystal, Mark Ellison, Charlotte Purdon, et al.
CNS Neuroscience & Therapeutics|January 1, 2010
A multicenter, placebo-controlled, double-blind, randomized study of efficacy and safety of ocinaplon (DOV 273,547) in generalized anxiety disorderPál Czobor, Phil Skolnick, Bernard Beer, et al.
Acta Neuropsychiatrica|April 11, 2015
Effect of NMDAR antagonists in the tetrabenazine test for antidepressants: comparison with the tail suspension testPhil Skolnick, Tomasz Kos, Janusz Czekaj, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 4, 2019
Fighting Fire with Fire: Development of Intranasal Nalmefene to Treat Synthetic Opioid OverdosePhilip Krieter, Shwe Gyaw, Roger Crystal, et al.
Cellular and Molecular Neurobiology|June 27, 2003
Enhancement of antidepressant potency by a potentiator of AMPA receptorsXia Li, Jeffrey M Witkin, Anne B Need, et al.
European Journal of Pharmacology|February 15, 2003
Antidepressant-like actions of DOV 21,947: a "triple" reuptake inhibitorPhil Skolnick, Piotr Popik, Aaron Janowsky, et al.
Journal of Clinical Pharmacology|January 31, 2019
Enhanced Intranasal Absorption of Naltrexone by Dodecyl Maltopyranoside: Implications for the Treatment of Opioid OverdosePhilip Krieter, Shwe Gyaw, C Nora Chiang, et al.
Life Sciences|October 17, 2003
"Broad spectrum" antidepressants: is more better for the treatment of depression?Phil Skolnick, Piotr Popik, Aaron Janowsky, et al.
Neuropharmacology|June 8, 2025
Reversal of a synthetic opioid overdose: Insights from a validated translational modelCeline M Laffont, Prasad Purohit, Amparo de la Peña, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 18, 2019
Pharmacokinetic Interaction between Naloxone and Naltrexone Following Intranasal Administration to Healthy SubjectsPhilip Krieter, C Nora Chiang, Shwe Gyaw, et al.
Pageof 6

Showing results (21-30 of 59) with videos related to

Sort By:
Pageof 6
Clinical Pharmacology in Drug Development|July 27, 2023
Pharmacokinetic Properties of an FDA-approved Intranasal Nalmefene Formulation for the Treatment of Opioid OverdoseRoger Crystal, Mark Ellison, Charlotte Purdon, et al.
CNS Neuroscience & Therapeutics|January 1, 2010
A multicenter, placebo-controlled, double-blind, randomized study of efficacy and safety of ocinaplon (DOV 273,547) in generalized anxiety disorderPál Czobor, Phil Skolnick, Bernard Beer, et al.
Acta Neuropsychiatrica|April 11, 2015
Effect of NMDAR antagonists in the tetrabenazine test for antidepressants: comparison with the tail suspension testPhil Skolnick, Tomasz Kos, Janusz Czekaj, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 4, 2019
Fighting Fire with Fire: Development of Intranasal Nalmefene to Treat Synthetic Opioid OverdosePhilip Krieter, Shwe Gyaw, Roger Crystal, et al.
Cellular and Molecular Neurobiology|June 27, 2003
Enhancement of antidepressant potency by a potentiator of AMPA receptorsXia Li, Jeffrey M Witkin, Anne B Need, et al.
European Journal of Pharmacology|February 15, 2003
Antidepressant-like actions of DOV 21,947: a "triple" reuptake inhibitorPhil Skolnick, Piotr Popik, Aaron Janowsky, et al.
Journal of Clinical Pharmacology|January 31, 2019
Enhanced Intranasal Absorption of Naltrexone by Dodecyl Maltopyranoside: Implications for the Treatment of Opioid OverdosePhilip Krieter, Shwe Gyaw, C Nora Chiang, et al.
Life Sciences|October 17, 2003
"Broad spectrum" antidepressants: is more better for the treatment of depression?Phil Skolnick, Piotr Popik, Aaron Janowsky, et al.
Neuropharmacology|June 8, 2025
Reversal of a synthetic opioid overdose: Insights from a validated translational modelCeline M Laffont, Prasad Purohit, Amparo de la Peña, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 18, 2019
Pharmacokinetic Interaction between Naloxone and Naltrexone Following Intranasal Administration to Healthy SubjectsPhilip Krieter, C Nora Chiang, Shwe Gyaw, et al.
Pageof 6